Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma

Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approxim...

Full description

Saved in:
Bibliographic Details
Published in:J Exp Clin Cancer Res
Main Authors: Liu, Ziyu, Lin, Yan, Zhang, Jinyan, Zhang, Yumei, Li, Yongqiang, Liu, Zhihui, Li, Qian, Luo, Ming, Liang, Rong, Ye, Jiazhou
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827249/
https://ncbi.nlm.nih.gov/pubmed/31684985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1412-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items